Industry News
-
-
-
Dr Poonam Khetarpal Singh, regional director of the World Health Organisation (WHO) South-East Asia region, reported that there is no airborne case of the COVID-19 known yet.
-

Hydroxychloroquine and a related drug, chloroquine, are currently under evaluation in clinical trials for the treatment of COVID-19. Also, there are few results suggested that Hydroxychloroquine is effective against COVID-19. Three pharma giants Novartis, Mylan and Teva Pharma announced that they will donate millions of doses of hydroxychloroquine to support the global COVID-19 pandemic response.
-
-
Zydus Cadila, an innovation-driven global pharmaceutical company announced that the Drug Controller General of India (DCGI) has approved its New Drug Application (NDA) for Saroglitazar for the treatment of Non-Cirrhotic Non-Alcoholic SteatoHepatitis (NASH) in India.
-
The Government has made amendments in the export policy and restricted export of specified APIs (Active Pharmaceutical Ingredients) and formulations made from 13 APIs for safety purpose due to COVID-19 outbreak in India. A notification issued by Directorate General of Foreign Trade, Commerce and Industry says that the restrictions will come into immediate effect and until further orders.
-

Sanofi Pasteur, the vaccines global business unit of Sanofi, will leverage previous development work for a SARS vaccine which may unlock a fast path forward for developing a COVID-19 vaccine. Sanofi will collaborate with the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response, expanding the company’s long-standing partnership with BARDA.
-

The World Health Organization’s new action plan to speed up universal access to safe blood and blood products pulls together existing recommendations and recommends new improved ways of working. It’s the start of a four-year collaborative effort to improve blood transfusion and blood-based therapies in all countries.
-

Acacia Pharma Group plc a hospital pharmaceutical company focused on the development and commercialization of new products aimed at improving the care of patients undergoing significant treatments such as surgery, other invasive procedures, or cancer chemotherapy, announces that the US Food and Drug Administration (FDA) has approved BARHEMSYS® (amisulpride injection) for the prevention and treatment of PONV in adult patients.



